Stockreport

Aptevo Therapeutics Begins Patient Dosing in Phase 2 Clinical Trial of Otlertuzumab in Peripheral T-Cell Lymphoma

Aptevo Therapeutics Inc.  (APVO) 
Last aptevo therapeutics inc. earnings: 8/9 09:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.aptevotherapeutics.com/investor-overview
PDF SEATTLE, Jan. 08, 2018 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeu [Read more]